--- title: "The HK Market's Bottom Drawer: AI Data Centers, Robot Surgeons, and Regulatory Messes" type: "News" locale: "en" url: "https://longbridge.com/en/news/293012891.md" description: "The unclassified corners of the Hong Kong market are a wild mix. SUNeVision rides the AI wave, Grand Pharma clings to its nuclear medicine moat, and PSBC struggles with compliance. Finding alpha here is a true test of your stomach." datetime: "2026-07-17T09:12:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293012891.md) - [en](https://longbridge.com/en/news/293012891.md) - [zh-HK](https://longbridge.com/zh-HK/news/293012891.md) generator: "portal-rs" --- # The HK Market's Bottom Drawer: AI Data Centers, Robot Surgeons, and Regulatory Messes We spend so much time obsessing over the grand narratives of Tencent and Alibaba that we forget to look in the bottom drawer of the Hong Kong market. When you group a bunch of unclassified, overlooked tickers together, you get a completely fragmented world that feels like a pawn shop filled with unsold inventory and mystery boxes. You have tech infrastructure plays desperately trying to ride the AI hype, aggressive medical device makers pitching global expansion, and lumbering state-owned enterprises mired in compliance scandals. If you are digging around this eclectic mix for alpha, this is a true test of your stock-picking stomach. This is stupid, and here's why. Let's start with the few actually trying to tell a modern story. SUNeVision (1686.HK) is arguably the only one here that actually piques my interest. As Hong Kong's largest data center operator, it just dragged the occupancy rate of its MEGA IDC phase 1 from a miserable 30% up to roughly 70% thanks to a single major client. Wall Street analysts are tripping over themselves to maintain their buy ratings. In an era where everyone is scrambling for compute power, being the landlord isn't a bad gig, and its stock has rebounded recently to reflect that. Then there's Zhen Health Medical (2697.HK). It recently hit a new post-IPO high, jumping over 20% in a single intraday session this month. They are banking on a CE certification by late 2026 for their percutaneous surgical robots to unlock European markets. But global medical device expansion is never a walk in the park. Good luck with that. The traditional manufacturing and energy plays are predictably boring. Dongfang Electric (1072.HK) posted a solid 37.4% year-over-year jump in Q1 2026 net profit, sitting comfortably on a massive backlog of orders that will keep them busy for years. Power Assets Holdings (6.HK) and Grand Pharmaceutical (512.HK) are surviving on their respective moats—the former via steady profit contributions from UK infrastructure and the latter clutching its cardiovascular and nuclear medicine portfolio. They are fundamentally sound, but their recent stock performance is hardly thrilling. Joyson Electronic (699.HK) secured RMB 97B in new orders in 2025 and is making noise about smart driving and 6G modules. But in the current automotive price war, revenue growth doesn't always translate to margin expansion. As for Petro-king Oilfield Services (2178.HK) and Time Interconnect Technology (1729.HK), they are essentially invisible in this cycle, merely drifting with the broader market without any clear near-term catalysts. Finally, we have the outright messes. Postal Savings Bank of China (1658.HK) has been slapped with over RMB 8.5M in fines in Fujian province alone this year, largely due to sloppy due diligence on personal business loans. When your compliance infrastructure looks like a sieve, investors notice. Sinofert (297.HK) is even worse—a production director at one of its subsidiaries was placed under investigation in June 2026. Sure, they are still dutifully paying out final dividends, but this level of management oversight is exactly why so many investors discount these traditional sectors. If you are shopping in these corners, you better bring your own lightning rod. *This article does not constitute investment advice.* ### Related Stocks - [02697.HK](https://longbridge.com/en/quote/02697.HK.md) - [01686.HK](https://longbridge.com/en/quote/01686.HK.md) - [01072.HK](https://longbridge.com/en/quote/01072.HK.md) - [00006.HK](https://longbridge.com/en/quote/00006.HK.md) - [01729.HK](https://longbridge.com/en/quote/01729.HK.md) - [02178.HK](https://longbridge.com/en/quote/02178.HK.md) - [00699.HK](https://longbridge.com/en/quote/00699.HK.md) - [00512.HK](https://longbridge.com/en/quote/00512.HK.md) - [00297.HK](https://longbridge.com/en/quote/00297.HK.md) - [01658.HK](https://longbridge.com/en/quote/01658.HK.md) ## Related News & Research - [Dongfang Electric Corporation: Net profit jumped 42% on steady revenue growth and margin gains, with no interim dividend declared](https://longbridge.com/en/news/296917941.md) - [PSBC 1H26 Net Profit Up 4.6% to RMB51.5B; Interim DPS Hikes 8.1% to RMB0.133](https://longbridge.com/en/news/297298563.md) - [Sinofert FY26 H1 profit attributable to owners rises 6.7% to RMB 1.18 billion; revenue increases 10.64% to RMB 16.28 billion](https://longbridge.com/en/news/296856995.md) - [Guangdong True Health signs strategic cooperation pact with General Technology Liaoning Pharmaceutical](https://longbridge.com/en/news/296881513.md) - [Ningbo Joyson FY26 H1 net profit falls 4.5% to RMB 867.78 million; revenue drops 7.4% to RMB 28.09 billion](https://longbridge.com/en/news/296927134.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**